MedTrace Logo

Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

NCT06043427 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2026-05-12

No results posted yet for this study

Summary

This study is being done to answer the following question:

Can the chance of gastroesophageal cancer growing or spreading be lowered by adding a drug called zanidatamab to the usual combination of drugs?

We are doing this study because we want to find out if this approach is better or worse than the usual approach for this type of cancer. The usual approach is defined as care most people get for gastroesophageal cancer

Conditions

  • Gastroesophageal Adenocarcinoma

Interventions

DRUG

Paclitaxel

80 mg/m²

DRUG

Ramucirumab

8 mg/kg

DRUG

Zanidatamab

Dose and schedule to be assigned at enrollment

Sponsors & Collaborators

Principal Investigators

  • Elena Elimova · University Health Network, Princess Margaret Cancer Centre, Toronto ON Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-16
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06043427 on ClinicalTrials.gov